EKB Journal Management System
1.

Serum and Pleural Fluid Megakaryocyte Potentiating Factor: A Promising Marker for Malignant Pleural Mesothelioma Diagnosis

Volume 93, Issue 06, June 2025, Pages 761-768
AMIRA I. MOUSTAFA, M.D.*; RANA K. ELSAYED, M.D.*; HEBAT-ALLAH MOSA AHMED, M.D.*; KHALED M. KAMEL, M.D.*; ALAA-ELDIN O. SHALABY, M.D.*;; WALAA A. ATEYA, M.D.** AHMED SAYED MAHMOUD, M.D.***
2.

Role of CT and modified Response Evaluation Criteria in Solid Tumors (RECIST criteria) in response evaluation of malignant pleural mesothelioma

Volume 3, Issue 2, June 2020, Pages 55-66
Hend Galal Eldeen Mohamed Ali Hassan; Khalid Esmat Allam; Basma Abdelbaset Mohamed; Shaimaa El metwally EL diasty EL metwally
3.

The Significance of BRCA-associated Protein (BAP1) and Calretinin Expression in Malignant Pleural Mesothelioma and Non-small Cell Lung Carcinoma: An Immunohistochemical Study

Volume 25, Issue 4, July 2019, Pages 567-576
Hend Alaa Eldin Hadhoud; Yehia Elalfy Ali; Amira Amin Salem; Mai Mohammed Abdelwahab
4.

ENVIRONMENTAL AND OCCUPATIONAL RISK FACTORS AND PREDICTORS OF SURVIVAL AMONG MALIGNANT PLEURAL MESOTHELIOMA PATIENTS

Volume 43, Issue 2, May 2019, Pages 245-258
Abdel-Hamid M A; Ammar N E; Shoman A; Elhoussinie M; Elwakeel H
5.

Four versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelima: Results of a Randomized Phase II Study

Volume 14, Issue 2, December 2018, Pages 50-52
Ahmed Nagy; Hesham Elwakeel; Omar Abdel-Rahman
6.

Intensity Modulated Radiation Therapy versus Supportive Care in Malignant Pleural Mesothelioma: A Pilot Study for Treatment Outcomes and Cost-Effective Expectations

Volume 14, Issue 1, June 2018, Pages 6-11
Mahmoud Ellithy; Nermeen Ashoush; Khalid El Shahat; Emad Ahmed; Mahmoud Abdelsalam
7.

A Retrospective Analysis of Epidemiology Prognostic Factor and Response of Treatment of Malignant Pleural Mesothelioma

Volume 70, Issue 1, January 2018, Pages 155-170
Dalia A El-Khodary; Khaled K Elghoniemy; Wesam R EL Ghamry; Heba R Saleh